| The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis RL O′ Donnell, A McCormick, A Mukhopadhyay, LC Woodhouse, ... PloS one 9 (3), e90604, 2014 | 59 | 2014 |
| Advanced ovarian cancer displays functional intratumor heterogeneity that correlates to ex vivo drug sensitivity RL O’Donnell, A Kaufmann, L Woodhouse, A McCormick, PA Cross, ... International Journal of Gynecologic Cancer 26 (6), 2016 | 12 | 2016 |
| Evaluation of the clinical utility of genomic profiling to inform selection of clinical trial therapy in salivary gland cancer S Rack, L Feeney, B Hapuarachi, H Adderley, L Woodhouse, G Betts, ... Cancers 14 (5), 1133, 2022 | 6 | 2022 |
| The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and … TDJ Walker, ZF Faraahi, MJ Price, A Hawarden, CA Waddell, B Russell, ... British Journal of Cancer 128 (9), 1765-1776, 2023 | 5 | 2023 |
| 1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience L Moliner, L Woodhouse, S Ahmed, S Bhagani, P Sevak, A Vijay, N Steele, ... Annals of Oncology 33, S1251, 2022 | 4 | 2022 |
| Metastatic bone disease from an occult renal primary L Woodhouse, J Watkins, S Navalkissoor, R Gillmore BMJ Case Reports CP 12 (4), e227657, 2019 | 3 | 2019 |
| Development of a Functional Assay to Determine the Nucleotide Excision Repair Status of Epithelial Overian Cancer L Woodhouse, A McCormick, R O'Donnell, A Kaufmann, R Edmondson 15th Biennial Meeting of the International Gynecologic Cancer Society, 2014 | 2 | 2014 |
| Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer F Coe, V Misra, Y McCabe, H Adderley, L Woodhouse, Z Ayub, X Wang, ... Breast Cancer Research and Treatment, 1-9, 2022 | 1 | 2022 |
| Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade … BS Hapuarachi, R Lee, A Khan, L Woodhouse, V Kounnis, F Britton, ... Journal of Clinical Oncology 39 (15_suppl), 4039-4039, 2021 | 1 | 2021 |
| Ovarian Cancer LC Woodhouse, RJ Edmondson International Encyclopedia of Public Health, 2016 | 1 | 2016 |
| 94 Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with METexon 14 skipping mutation M Smith, M Carter, L Woodhouse, H Adderley, G Morrissey, K Brown, ... Lung Cancer 190, 2024 | | 2024 |
| KRAS mutant lung adenocarcinoma is associated with distinct mutational signature profiles L Woodhouse, A Hawari, A Gruber, C Lindsay, D Wedge Cancer Research 84 (6_Supplement), 1746-1746, 2024 | | 2024 |
| RAS-Bio a unique pan-cancer biobank for RAS-driven tumors M Carter, KD Brown, H Adderley, G Morrissey, L Woodhouse, J Weaver, ... Cancer Research 84 (6_Supplement), 2494-2494, 2024 | | 2024 |
| Abstract B014: Characterization of Nectin-4 protein expression in non-small cell lung cancer patients SM Santos, E Darlington, L Woodhouse, N Peters, E Peat, A De Rienzo, ... Molecular Cancer Therapeutics 22 (12_Supplement), B014-B014, 2023 | | 2023 |
| Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC) J Lewis, L Woodhouse, H Adderley, M Carter, K Brown, G Morrissey, ... | | 2023 |
| The heterogeneity of the DNA damage response landscape determines patient outcomes in ovarian cancer TDJ Walker, ZF Faraahi, MJ Price, A Hawarden, CA Waddell, B Russell, ... bioRxiv, 2021.08. 03.454868, 2021 | | 2021 |
| V6 PRIMROSE: A national trainee collaborative-led, multicentre prospective audit on the care of breast cancer patients with central nervous system disease in the UK MP Lythgoe, VWT Cheng, HS McKenzie, A Kwan, A Konstantis, R Ma, ... BJS Open 5 (Supplement_1), zrab034. 005, 2021 | | 2021 |
| Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic … R Dacie, L Woodhouse, D Mullan, A Lamarca Cureus 12 (10), 2020 | | 2020 |
| The genomic and functional status of TP53 in ovarian cancer: biomarker for chemotherapy outcome and determinant of response to MDM2 inhibitors M Zanjirband Newcastle University, 2017 | | 2017 |
| A functional assay to determine the nucleotide excision repair status of ovarian cancer patients FZ Faraahi, LC Woodhouse, A McCormick, M Price, RJ Edmondson 19th International Meeting of the European Society of Gynaecological …, 2015 | | 2015 |
